MedWatch

Analyst comments on Novo Nordisk's record-breaking stock price

On Tuesday, Novo Nordisk’s stock price has passed a milestone, which could indicate that investors are hoping for a guidance upgrade later this year, Sydbank Analyst Søren Løntoft Hansen says.

Photo: Novo Nordisk / PR

A run of positive news of a smaller size is why Novo Nordisk’s stock price has increased so much that it broke its previous record on Tuesday, assesses Senior Equity Analyst at Sydbank Søren Løntoft Hansen.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs